Tricia Rodriguez, Truveta senior applied research scientist & lead study author, explains the study findings concerning why ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

GLP-1 drugs like Ozempic have swept the world as effective therapies for far more than their original target of diabetes.

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of ...

While diabetes and obesity pose many of the same risks to the body, they aren't exactly the same, so it's hard to know whether that also influenced the results.For example, the study found GLP-1 ...